He Ji-gang, Shen Zhen-ya, Teng Xiao-mei, Yu Yun-sheng, Huang Hao-yue, Ye Wen-xue, Ding Ying-long
Cardiovascular Surgery, Affiliated First Hospital, Soochow University, Suzhou 215006, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Mar;41(3):210-4.
To search for the bone mesenchymal stem cell (MSC) subgroup which might be more effective on repairing myocardial damage.
In this experiment, four MSC subgroups were defined based on the surface differentiation antigen detection of mouse bone mesenchymal stem cells (mBMSCs): SCA-1(+)/CD45(+)/CD31(+), SCA-1(+)/CD45(+)/CD31(-), SCA-1(+)/CD45(-)/CD31(-) and SCA-1(+)/CD45(-)/CD31(+). These subgroup cells and unselected mBMSCs were injected into infarcted mouse via tail vein. Echocardiographic heart function measurement and in vivo DiR-labeled stem cells imaging were performed at 48 h after injection. In situ C-kit (a flag antigen of cardiac stem cells) and cardiac-specific differentiation antigen immunohistochemistry detection was made in the infarcted myocardium.
The capacity of the SCA-1(+)/CD45(+)/CD31(+) cells on improving heart function was significantly higher than other cell groups (all P < 0.05). In vivo imaging showed that the mean fluorescence intensity of the SCA-1(+)/CD45(+)/CD31(+) cells was also higher than other cell groups (all P < 0.05). Number of cardiac stem cells in the infracted myocardium was significantly increased after the injection of all subgroup cells and unsorted mBMSCs cells for 48 h compared untreated infracted myocardium. The capacity of mobilizing cardiac stem cells is as follows: SCA-1(+)/CD45(+)/CD31(+) >SCA-1(+)/CD45(-)/CD31(+) >SCA-1(+)/CD45(-)/CD31(-) >SCA-1(+)/CD45(+)/CD31(-).
The SCA-1(+)/CD45(+)/CD31(+) subgroups of mBMSCs exhibites the highest capacity to improve cardiac function after myocardial infarction and to mobilize autologous cardiac stem cells compared with other mBMSCs subgroups and unsorted mBMSCs cells.
寻找可能对修复心肌损伤更有效的骨髓间充质干细胞(MSC)亚群。
在本实验中,根据小鼠骨髓间充质干细胞(mBMSCs)的表面分化抗原检测定义了四个MSC亚群:SCA-1(+)/CD45(+)/CD31(+)、SCA-1(+)/CD45(+)/CD31(-)、SCA-1(+)/CD45(-)/CD31(-)和SCA-1(+)/CD45(-)/CD31(+)。将这些亚群细胞和未分选的mBMSCs经尾静脉注射到梗死小鼠体内。注射后48小时进行超声心动图心脏功能测量和体内DiR标记干细胞成像。对梗死心肌进行原位C-kit(心脏干细胞的标记抗原)和心脏特异性分化抗原免疫组织化学检测。
SCA-1(+)/CD45(+)/CD31(+)细胞改善心脏功能的能力明显高于其他细胞组(所有P<0.05)。体内成像显示,SCA-1(+)/CD45(+)/CD31(+)细胞的平均荧光强度也高于其他细胞组(所有P<0.05)。与未处理的梗死心肌相比,注射所有亚群细胞和未分选的mBMSCs细胞48小时后,梗死心肌中的心脏干细胞数量显著增加。动员心脏干细胞的能力如下:SCA-1(+)/CD45(+)/CD31(+)>SCA-1(+)/CD45(-)/CD31(+)>SCA-1(+)/CD45(-)/CD31(-)>SCA-1(+)/CD45(+)/CD31(-)。
与其他mBMSCs亚群和未分选的mBMSCs细胞相比,mBMSCs的SCA-1(+)/CD45(+)/CD31(+)亚群在心肌梗死后改善心脏功能和动员自体心脏干细胞方面表现出最高的能力。